Zevra Therapeutics
ZVRA----
Zevra Therapeutics (ZVRA)
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company dev...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Zevra Therapeutics Analyst Rating
View MoreForecast & Rating
Jul 13, 2026Price forecast
$27.89188.41%
Forecast & RatingStrong buy
9analysts
- Strong buy77.78%
- Buy22.22%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- benzinga_article · 7 hours ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
- StockTitan · 15 hours ago
Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union | ZVRA Stock News
- PUBT · 2 days ago, 06:30 AM
Zevra Therapeutics schedules Q2 earnings call
- Simplywall · Jul 2 at 11:57 AM
Zevra Therapeutics (ZVRA) Following Russell Index Additions Is The Stock Still Undervalued
- PUBT · Jun 23 at 03:17 PM
Zevra Therapeutics Chief Legal & Compliance Rahsaan Thompson sells 34,557 shares for $438,216.86
- Tip Ranks · Jun 23 at 10:05 AM
Zevra Therapeutics: New Infant MIPLYFFA Data Reinforce Core NPC Role; Buy Rating and $26 Price Target Reiterated
